Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Delivery
Return to: PBR Home | Drug Research | Drug Delivery

Drug Delivery

Pulmatrix iSPERSE demonstrates capability to formulate drugs By PBR Staff Writer
Pulmatrix has demonstrated iSPERSE capabilities for inhaled dry powder delivery of antibiotics, antibodies and other macromolecules.
Drug Research > Drug Delivery > News
FDA approves Stiefel NDA for Fabior foam, 0.1% By PBR Staff Writer
The FDA has approved Stiefel's new drug application (NDA) for Fabior (tazarotene) foam, 0.1%, to treat acne vulgaris in patients 12 years of age and older.
Drug Research > Drug Delivery > News AstraZeneca Symbicort shows similar safety profile as Budesonide for asthma By PBR Staff Writer
AstraZeneca has published a new study that demonstrates that Symbicort Inhalation Aerosol 320/9 µg twice daily has a safety profile similar to Budesonide pressurized metered-dose inhaler (pMDI) 320 µg twice daily for asthma.
Drug Research > Drug Delivery > News
See more Drug Delivery news

Latest Drug Delivery News and Insight

View all Drug Delivery news or find news targeted to your interests
Pulmatrix iSPERSE demonstrates capability to formulate drugs
16 May 2012 | By PBR Staff Writer
Pulmatrix has demonstrated iSPERSE capabilities for inhaled dry powder delivery of antibiotics, antibodies and other macromolecules.
Drug Research > Drug Delivery > News
FDA approves Stiefel NDA for Fabior foam, 0.1%
14 May 2012 | By PBR Staff Writer
The FDA has approved Stiefel's new drug application (NDA) for Fabior (tazarotene) foam, 0.1%, to treat acne vulgaris in patients 12 years of age and older.
Drug Research > Drug Delivery > News
AstraZeneca Symbicort shows similar safety profile as Budesonide for asthma
11 May 2012 | By PBR Staff Writer
AstraZeneca has published a new study that demonstrates that Symbicort Inhalation Aerosol 320/9 µg twice daily has a safety profile similar to Budesonide pressurized metered-dose inhaler (pMDI) 320 µg twice daily for asthma.
Drug Research > Drug Delivery > News
SK Biopharmaceuticals signs licensing deal with Hanmi for DZNS technology
10 May 2012 | By PBR Staff Writer
SK Biopharmaceuticals has signed a licensing agreement with Hanmi Pharmacutical for diazepam nasal spray (DZNS) technology.
Drug Research > Drug Delivery > News
Oramed wins Israeli government grant to advance oral insulin studies
10 May 2012 | By PBR Staff Writer
Oramed, a wholly owned Israeli subsidiary of Oramed Pharmaceuticals, has received government grant of NIS2m (approximately $540,000) in Israel.
Drug Research > Drug Delivery > News
GE Healthcare increases availability of Optison suspension
09 May 2012 | By PBR Staff Writer
GE Healthcare has extended the supply agreement with its contract manufacture for its Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP).
Drug Research > Drug Delivery > News
Bayer Yakuhin, Santen ink co-promotion deal for Eylea in Japan
08 May 2012 | By PBR Staff Writer
Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin has signed a co-promotion agreement with Santen Pharmaceutical for Eylea (aflibercept) injection in Japan.
Drug Research > Drug Delivery > News
Sunovion to launch Zetonna nasal aerosol for allergic rhinitis
08 May 2012 | By PBR Staff Writer
Sunovion Pharmaceuticals is set to launch Zetonna (ciclesonide) nasal aerosol, a non-aqueous, dry nasal aerosol spray for allergic rhinitis in the third quarter of 2012 in the US.
Drug Research > Drug Delivery > News
Azelon completes clinical trial to compare nasal spray ZT-034 to Forteo
03 May 2012 | By PBR Staff Writer
Azelon Pharmaceuticals has completed a phase 2a trial comparing nasal spray ZT-034 to Forteo administered by subcutaneous injection and placebo in women with low bone mass.
Drug Research > Drug Delivery > News
Strength of Aptalis Pharmaceutical Technologies Patents Confirmed by AMRIX® Verdict
02 May 2012
Aptalis Pharmatech, Inc. (previously known as Eurand, Inc.) and Cephalon, Inc. a wholly-owned subsidiary of Teva Pharmaceuticals Industries Ltd, and Anesta AG prevailed in their appeal to the U.S. Court of Appeals for the Federal Circuit which reversed a lower court’s determination and held that two patents covering the AMRIX® muscle relaxant (Cyclobenzaprine Hydrochloride Extended-Release Capsules) are valid.
Drug Research > Drug Delivery > Press Releases
View all Drug Delivery news or find news targeted to your interests

Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential 08 December 2010 GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500